The latest weekly summary of Yellow Card reporting has been published by the Medicines & Healthcare products Regulatory Agency (MHRA), including updated numbers of cerebral venous sinus thrombosis (CVST) and other thrombosis events with low platelets.
Dr Peter English, Retired Consultant in Communicable Disease Control, Former Editor of Vaccines in Practice Magazine, Immediate past Chair of the BMA Public Health Medicine Committee, said:
“This latest weekly summary of Yellow Card reporting provides some detail on reports to the Medicines and Healthcare products Regulatory Agency (MHRA) relating to clotting events following Coronavirus vaccines.1 The context is one in which some countries (despite assurances from their regulators) have restricted the use of the AstraZeneca coronavirus vaccine, following reports suggesting a possible excess of cases of clotting disorders – in particular, of cerebral sinus venous thrombosis (CSVT) – in people who have received vaccine. The MHRA report states: “Our rigorous review into the UK reports of rare and specific types of blood clots is ongoing. Up to and including 24 March, we have received 22 reports of cerebral venous sinus thrombosis (CVST) and 8 reports of other thrombosis events with low platelets, out of a total of 18.1 million doses of COVID-19 Vaccine AstraZeneca given by that date. There were no reports for the Pfizer/BioNTech vaccine. To note, the current analysis prints include data up to and including the 21 March.